Zai Lab (ZLAB) said late Wednesday that China's National Medical Products Administration has accepted its marketing application for Tivdak, a therapy for treating certain patients with cervical cancer.
The company said the application is supported by a phase 3 study in which Tivdak demonstrated a 45% reduction in the risk of death compared to chemotherapy in the China subpopulation that had received prior standard systemic therapies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.